FDA Oks Genentech’ Actemra To Treat CAR T Cell-Induced Cytokine Release Syndrome – Markets Insider
|
FDA Oks Genentech' Actemra To Treat CAR T Cell-Induced Cytokine Release Syndrome
Markets Insider (RTTNews) – Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or … |
